A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Sarizotan (Primary)
  • Indications Rett syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms STARS
  • Sponsors Newron Pharmaceuticals
  • Most Recent Events

    • 25 Oct 2017 According to a Newron Pharmaceuticals media release, this study will be presented at European Rett Syndrome Congress November 2017.
    • 14 Sep 2017 Newron is working towards completion of recruitment by the end of 2017, according to a company media release.
    • 23 Jun 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top